Jefferies Group Comments on Immunomedics Inc.’s Q1 2017 Earnings (IMMU)
Immunomedics Inc. (NASDAQ:IMMU) – Equities research analysts at Jefferies Group issued their Q1 2017 earnings per share estimates for Immunomedics in a research report issued on Thursday. Jefferies Group analyst M. Andrews anticipates that the firm will earn ($0.12) per share for the quarter. Jefferies Group currently has a “Buy” rating on the stock.
Several other equities research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Immunomedics from a “hold” rating to a “strong sell” rating in a research note on Monday, August 22nd. Wells Fargo & Co. lowered shares of Immunomedics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 21st.
Shares of Immunomedics (NASDAQ:IMMU) traded down 1.15% during midday trading on Friday, reaching $2.58. The company’s stock had a trading volume of 1,973,534 shares. The company’s market capitalization is $247.33 million. The stock has a 50 day moving average of $2.99 and a 200-day moving average of $3.03. Immunomedics has a 1-year low of $1.61 and a 1-year high of $5.44.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/jefferies-group-comments-on-immunomedics-inc-s-q1-2017-earnings-immu.html
Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.06.
In other Immunomedics news, Director Don C. Stark sold 9,900 shares of the company’s stock in a transaction dated Wednesday, August 24th. The shares were sold at an average price of $2.97, for a total value of $29,403.00. Following the completion of the transaction, the director now owns 55,848 shares in the company, valued at approximately $165,868.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Mary E. Paetzold sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 23rd. The stock was sold at an average price of $2.98, for a total transaction of $44,700.00. Following the completion of the transaction, the director now owns 82,474 shares of the company’s stock, valued at approximately $245,772.52. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of IMMU. BlackRock Group LTD boosted its position in Immunomedics by 108.6% in the second quarter. BlackRock Group LTD now owns 46,962 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 24,444 shares during the period. Creative Planning boosted its position in Immunomedics by 0.9% in the second quarter. Creative Planning now owns 58,485 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 510 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Immunomedics during the second quarter valued at approximately $161,000. Chicago Equity Partners LLC purchased a new position in Immunomedics during the second quarter valued at approximately $258,000. Finally, Rhumbline Advisers boosted its position in Immunomedics by 13.0% in the second quarter. Rhumbline Advisers now owns 115,948 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 13,313 shares during the period. Hedge funds and other institutional investors own 53.79% of the company’s stock.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.